IBMS BoneKEy | Perspective
Insights into the antitumor effects of bisphosphonates from preclinical models and potential clinical implications
Philippe Clézardin
DOI:10.1138/20090381
Abstract
Since the observation that bisphosphonates act as potent inhibitors of osteoclast-mediated bone resorption, there is now a growing body of preclinical and clinical evidence that they may also exhibit direct and indirect antitumor activities through inhibition of tumor cell functions, enhancement of the cytotoxic activity of chemotherapy agents, stimulation of antitumor immune reactions and inhibition of tumor angiogenesis. Current insights and fronts of ongoing research on the antitumor effects of bisphosphonates in animal models of human cancers are presented in this review. Moreover, the clinical importance of these experimental findings is also discussed in light of the adjuvant use of bisphosphonates in several recent, large, phase III clinical trials in patients with early breast cancer.
This work is licensed under a
Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License.